Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.19 EUR
Change Today -0.07 / -3.10%
Volume 25.7K
NEU On Other Exchanges
Symbol
Exchange
Stuttgart
As of 11:39 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

neuron bio sa (NEU) Snapshot

Open
€2.20
Previous Close
€2.26
Day High
€2.20
Day Low
€2.16
52 Week High
03/17/15 - €3.28
52 Week Low
10/30/14 - €0.60
Market Cap
18.2M
Average Volume 10 Days
86.2K
EPS TTM
€-0.19
Shares Outstanding
8.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEURON BIO SA (NEU)

Related News

No related news articles were found.

neuron bio sa (NEU) Related Businessweek News

No Related Businessweek News Found

neuron bio sa (NEU) Details

Neuron BioPharma, S.A. discovers and develops compounds to prevent or treat various neurodegenerative diseases. The company focuses its research on the Alzheimer’s disease. Neuron BioPharma, S.A. was founded in 2005 and is based in Granada, Spain.

Founded in 2005

neuron bio sa (NEU) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

neuron bio sa (NEU) Key Developments

Neuron Bio, SA Auditor Raises 'Going Concern' Doubt

Neuron Bio, SA filed its Annual on May 05, 2015 for the period ending Dec 31, 2014. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Neuron Biopharma, S.A. Presents at 10th Foro MedCap, May-27-2014

Neuron Biopharma, S.A. Presents at 10th Foro MedCap, May-27-2014 . Venue: Palacio de la Bolsa, Plaza de la Lealtad, 1, 28014 Madrid, Spain.

Neuron Biopharma, S.A. Auditor Raises 'Going Concern' Doubt

Neuron Biopharma, S.A. filed its Annual on Apr 24, 2014 for the period ending Dec 31, 2013. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEU:SM €2.19 EUR -0.07

NEU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NEU.
View Industry Companies
 

Industry Analysis

NEU

Industry Average

Valuation NEU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.2x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEURON BIO SA, please visit www.neuronbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.